Meyer T J, Pearlman N W, Siebert P E, Murphy J R, White M J, Zaloznik A, Braun T, Rempel P
Cancer Treat Rep. 1986 Jun;70(6):711-4.
Forty-seven patients with stage III lung cancer from four institutions in the Denver area were entered in a study comparing two regimens of chemotherapy. The patients were randomized into two groups: Group A received lomustine, cyclophosphamide, vincristine, cisplatin, and doxorubicin monthly; Group B received the five-drug regimen on Months 1, 3, and 5 and received 5-FU by constant infusion, methotrexate, and mitomycin on Months 2, 4, and 6. The age, extent of disease, Karnofsky score, prior therapy, and average number of chemotherapy courses received in each group were comparable. The median survival in Group A was 265 days and in Group B was 163 days (P greater than 0.25). There does not seem to be an advantage in survival in patients who are treated with the eight-drug regimen over the five-drug regimen.
来自丹佛地区四家机构的47例III期肺癌患者参与了一项比较两种化疗方案的研究。患者被随机分为两组：A组每月接受洛莫司汀、环磷酰胺、长春新碱、顺铂和阿霉素治疗；B组在第1、3和5个月接受五药方案治疗，并在第2、4和6个月持续输注5-氟尿嘧啶、甲氨蝶呤和丝裂霉素。两组患者的年龄、疾病范围、卡诺夫斯基评分、既往治疗情况以及接受化疗疗程的平均数量均具有可比性。A组的中位生存期为265天，B组为163天（P大于0.25）。接受八药方案治疗的患者在生存期方面似乎并不比接受五药方案治疗的患者更具优势。
